PL4004056T3 - Przeciwciała anty-lewis y i ich zastosowanie w terapii nowotworów - Google Patents

Przeciwciała anty-lewis y i ich zastosowanie w terapii nowotworów

Info

Publication number
PL4004056T3
PL4004056T3 PL20756785.0T PL20756785T PL4004056T3 PL 4004056 T3 PL4004056 T3 PL 4004056T3 PL 20756785 T PL20756785 T PL 20756785T PL 4004056 T3 PL4004056 T3 PL 4004056T3
Authority
PL
Poland
Prior art keywords
lewis
antibodies
cancer therapy
cancer
therapy
Prior art date
Application number
PL20756785.0T
Other languages
English (en)
Inventor
Linda Gillian Durrant
Mireille VANKEMMELBEKE
Tina Rose PARSONS
Original Assignee
Scancell Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scancell Limited filed Critical Scancell Limited
Publication of PL4004056T3 publication Critical patent/PL4004056T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20756785.0T 2019-07-31 2020-07-31 Przeciwciała anty-lewis y i ich zastosowanie w terapii nowotworów PL4004056T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1910899.2A GB201910899D0 (en) 2019-07-31 2019-07-31 Binding members
PCT/EP2020/071725 WO2021019095A1 (en) 2019-07-31 2020-07-31 Binding members

Publications (1)

Publication Number Publication Date
PL4004056T3 true PL4004056T3 (pl) 2026-04-20

Family

ID=67990349

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20756785.0T PL4004056T3 (pl) 2019-07-31 2020-07-31 Przeciwciała anty-lewis y i ich zastosowanie w terapii nowotworów

Country Status (16)

Country Link
US (1) US20220267465A1 (pl)
EP (1) EP4004056B1 (pl)
JP (1) JP7604452B2 (pl)
KR (1) KR20220038445A (pl)
CN (1) CN114585648B (pl)
AU (1) AU2020322106A1 (pl)
BR (1) BR112022001523A2 (pl)
CA (1) CA3146889A1 (pl)
DK (1) DK4004056T3 (pl)
ES (1) ES3056660T3 (pl)
FI (1) FI4004056T3 (pl)
GB (1) GB201910899D0 (pl)
PL (1) PL4004056T3 (pl)
PT (1) PT4004056T (pl)
WO (1) WO2021019095A1 (pl)
ZA (1) ZA202200734B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021298824A1 (en) * 2020-06-30 2023-01-19 Pentixapharm Ag Humanized antibodies against lewis Y

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja) 1981-07-16 1983-01-22 Niles Parts Co Ltd 方位検出表示回路
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4971792A (en) 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0528767T3 (da) * 1991-08-21 2000-04-17 Novartis Ag antistofderivater
JPH06153955A (ja) * 1992-11-19 1994-06-03 Tosoh Corp フコシルｓｓｅａ−１を認識する抗体の遺伝子断片等
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
EP0796334A1 (en) * 1994-10-28 1997-09-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Tumor-specific antibody fragments, fusion proteins, and uses thereof
JPH10508202A (ja) * 1994-10-28 1998-08-18 アメリカ合衆国 腫瘍特異性抗体断片、融合タンパク質、およびそれらの使用
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
AU2003231554A1 (en) * 2002-04-30 2003-11-17 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
CN101547937A (zh) 2006-09-20 2009-09-30 阿拉纳治疗有限公司 抗Lewisy和Lewisb抗原的抗癌抗体
PT2702412T (pt) * 2011-04-28 2017-11-02 Sbi Biotech Co Ltd Anticorpo anti-proteína tirosina fosfatase humana do tipo recetor
KR20130020393A (ko) * 2011-08-19 2013-02-27 경희대학교 산학협력단 포르피로모나스 진지발리스(Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓ)의 ＦｉｍＡ 단백질 특이적 결합성을 갖는 항체, 항체를 코딩하는 유전자 및 항체를 포함하는 치주질환 치료용 조성물
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
GB201515094D0 (en) * 2015-08-25 2015-10-07 Univ Nottingham Sialyl-di-lewis a as expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
CA3000531A1 (en) * 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
EP3359575B1 (en) * 2015-10-09 2020-07-22 Florida State University Research Foundation, Inc. Antibodies specific for 4,6-diamino-5-(formylamino) pyrimidine and uses thereof
GB201912657D0 (en) * 2019-09-03 2019-10-16 Scancell Ltd Binding members
AU2021298824A1 (en) * 2020-06-30 2023-01-19 Pentixapharm Ag Humanized antibodies against lewis Y

Also Published As

Publication number Publication date
DK4004056T3 (da) 2025-12-15
JP7604452B2 (ja) 2024-12-23
CA3146889A1 (en) 2021-02-04
CN114585648B (zh) 2025-05-02
ES3056660T3 (en) 2026-02-23
US20220267465A1 (en) 2022-08-25
KR20220038445A (ko) 2022-03-28
CN114585648A (zh) 2022-06-03
BR112022001523A2 (pt) 2022-03-22
PT4004056T (pt) 2025-12-23
AU2020322106A1 (en) 2022-03-17
FI4004056T3 (fi) 2025-12-22
EP4004056B1 (en) 2025-09-24
ZA202200734B (en) 2025-12-17
GB201910899D0 (en) 2019-09-11
JP2022543367A (ja) 2022-10-12
WO2021019095A1 (en) 2021-02-04
EP4004056A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
ZA202002923B (en) Cd47 antibodies and uses thereof for treating cancer
SG11202011306TA (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
IL271221A (en) Antibodies that bind il-1beta for use in cancer therapy
NZ782442A (en) Antibodies that bind cd39 and uses thereof
ZA202100819B (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders
IL270596A (en) Antibodies containing heavy constant regions are adapted for use in cancer therapy
IL248511A0 (en) Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
EP3733703A4 (en) Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment
EP3258967A4 (en) Bivalent antibody directed against nkg2d and tumor associated antigens
IL320844A (en) Pharmaceutical combinations for tumor treatment involving anti-CD19 antibody and natural killer cell
IL258980A (en) Preparation of bispecific antigens and their use in cancer
IL275940A (en) Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment
IL281441A (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
SG11202003713TA (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
IL288728A (en) Anti-sortilin antibodies for use in therapy
IL292599A (en) tmem219 antibodies and medical uses thereof
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
PL4004056T3 (pl) Przeciwciała anty-lewis y i ich zastosowanie w terapii nowotworów
GB201810635D0 (en) Peptides and cancer treatment
IL308014A (en) Anti-galectin-9 antibodies and their therapeutic uses
ZA202204252B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
HUE066183T2 (hu) Karcinoembrionális antigén elleni ellenanyagok rákterápiához és diagnosztizáláshoz
EP4058478A4 (en) USES OF ANTI-EPCAM ANTIBODIES IN CANCER THERAPY
HK40054235A (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders